Cargando…
Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis
INTRODUCTION: The systemic inflammatory nature of systemic lupus erythematosus (SLE) is well patent not only in the diverse clinical manifestations of the disease but also in the increased risk of premature atherosclerosis and cardiovascular events (CVE), making SLE one of the most complex diseases...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796914/ https://www.ncbi.nlm.nih.gov/pubmed/29435447 http://dx.doi.org/10.3389/fmed.2017.00262 |
_version_ | 1783297571284844544 |
---|---|
author | Teixeira, Vítor Tam, Lai-Shan |
author_facet | Teixeira, Vítor Tam, Lai-Shan |
author_sort | Teixeira, Vítor |
collection | PubMed |
description | INTRODUCTION: The systemic inflammatory nature of systemic lupus erythematosus (SLE) is well patent not only in the diverse clinical manifestations of the disease but also in the increased risk of premature atherosclerosis and cardiovascular events (CVE), making SLE one of the most complex diseases to study and manage in clinical practice. AIM: To travel from old aspects to modern insights on the physiopathology, new molecular biomarkers, imaging methods of atherosclerosis assessment, and the potential treatments of atherosclerosis in SLE. METHODS: We conducted a literature search using PubMed database and performed a critical review. CONCLUSION/DISCUSSION: Several developments have taken place in the understanding of the relationship between SLE and premature atherosclerosis. Nevertheless, cardiovascular diseases are still the major cause of reduced life expectancy in SLE and the main cause of death. The lack of standardization methods for the imaging assessment of atherosclerosis in SLE and the multifactorial nature of the disease are well patriated in the difficulty of achieving consistent and reproducible results among studies that focus in cardiovascular risk assessment and prediction. A raising number of molecular biomarkers of atherosclerosis have been proposed, but the combination of several biomarkers and risk factors may better estimate cardiovascular disease risk. Moreover, the development of effective therapies to prevent progression of atherosclerosis and CVE shall address systemic inflammation. |
format | Online Article Text |
id | pubmed-5796914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57969142018-02-12 Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis Teixeira, Vítor Tam, Lai-Shan Front Med (Lausanne) Medicine INTRODUCTION: The systemic inflammatory nature of systemic lupus erythematosus (SLE) is well patent not only in the diverse clinical manifestations of the disease but also in the increased risk of premature atherosclerosis and cardiovascular events (CVE), making SLE one of the most complex diseases to study and manage in clinical practice. AIM: To travel from old aspects to modern insights on the physiopathology, new molecular biomarkers, imaging methods of atherosclerosis assessment, and the potential treatments of atherosclerosis in SLE. METHODS: We conducted a literature search using PubMed database and performed a critical review. CONCLUSION/DISCUSSION: Several developments have taken place in the understanding of the relationship between SLE and premature atherosclerosis. Nevertheless, cardiovascular diseases are still the major cause of reduced life expectancy in SLE and the main cause of death. The lack of standardization methods for the imaging assessment of atherosclerosis in SLE and the multifactorial nature of the disease are well patriated in the difficulty of achieving consistent and reproducible results among studies that focus in cardiovascular risk assessment and prediction. A raising number of molecular biomarkers of atherosclerosis have been proposed, but the combination of several biomarkers and risk factors may better estimate cardiovascular disease risk. Moreover, the development of effective therapies to prevent progression of atherosclerosis and CVE shall address systemic inflammation. Frontiers Media S.A. 2018-01-29 /pmc/articles/PMC5796914/ /pubmed/29435447 http://dx.doi.org/10.3389/fmed.2017.00262 Text en Copyright © 2018 Teixeira and Tam. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Teixeira, Vítor Tam, Lai-Shan Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis |
title | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis |
title_full | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis |
title_fullStr | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis |
title_full_unstemmed | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis |
title_short | Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis |
title_sort | novel insights in systemic lupus erythematosus and atherosclerosis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796914/ https://www.ncbi.nlm.nih.gov/pubmed/29435447 http://dx.doi.org/10.3389/fmed.2017.00262 |
work_keys_str_mv | AT teixeiravitor novelinsightsinsystemiclupuserythematosusandatherosclerosis AT tamlaishan novelinsightsinsystemiclupuserythematosusandatherosclerosis |